COVID-19 mRNA Vaccination Trends Among Immunocompromised Patients

References

1. 1.↵
   1. Parker EPK,
   2. Desai S,
   3. Marti M,
   4. et al

   . Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review. Lancet Glob Health 2022;10:e326–e328.

   OpenUrlCrossRef
2. 2.↵
   1. Singson JRC,
   2. Kirley PD,
   3. Pham H

   , COVID-NET Surveillance Teamet al. Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID-19–COVID-NET, 10 States, March 2020–February 2022. MMWR Morb Mortal Wkly Rep 2022;71:878–84.

   OpenUrlCrossRef
3. 3.↵
   1. Tenforde MW,
   2. Self WH,
   3. Adams K

   , Influenza and Other Viruses in the Acutely Ill (IVY) Networket al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA 2021;326:2043–54.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Deepak P,
   2. Kim W,
   3. Paley MA,
   4. et al

   . Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study. Ann Intern Med 2021;174:1572–85.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Lauring AS,
   2. Tenforde MW,
   3. Chappell JD

   , Influenza and Other Viruses in the Acutely Ill (IVY) Networket al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ 2022;376:e069761.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Boyarsky BJ,
   2. Werbel WA,
   3. Avery RK,
   4. et al

   . Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. JAMA 2021;325:1784–6.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Boyarsky BJ,
   2. Werbel WA,
   3. Avery RK,
   4. et al

   . Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA 2021;325:2204–6.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Chumsri S,
   2. Advani PP,
   3. Pai TS,
   4. et al

   . Humoral responses after SARS-CoV-2 mRNA vaccination and breakthrough infection in cancer patients. Mayo Clin Proc Innov Qual Outcomes 2022;6:120–5.

   OpenUrl
9. 9.↵
   1. Kamar N,
   2. Abravanel F,
   3. Marion O,
   4. Couat C,
   5. Izopet J,
   6. Bello AD

   . Three doses of an mRNA COVID-19 vaccine in solid-organ transplant recipients. N Engl J Med . 2021;385:661–2. Published online June 23.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Benotmane I,
    2. Gautier G,
    3. Perrin P,
    4. et al

    . Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses. JAMA 2021;326:1063–5.

    OpenUrlPubMed
11. 11.↵
    1. Saiag E,
    2. Grupper A,
    3. Avivi I,
    4. et al

    . The effect of a third-dose BNT162b2 vaccine on anti-sars-cov-2 antibody levels in immunosuppressed patients. Clin Microbiol Infect. 2022;28:735.e5–735.e8. Published online February 18.

    OpenUrlPubMed
12. 12.↵
    1. Shen C,
    2. Risk M,
    3. Schiopu E,
    4. et al

    . Efficacy of COVID-19 vaccines in patients taking immunosuppressants. Ann Rheum Dis 2022;81:875–80. Published online February 23.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    CDC. COVID-19 vaccines for people who are moderately or severely immunocompromised. Centers for Disease Control and Prevention. Published February 11, 2020. Accessed November 25, 2022. Available at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html.
14. 14.↵
    1. Duly K,
    2. Farraye FA,
    3. Bhat S

    . COVID-19 vaccine use in immunocompromised patients: a commentary on evidence and recommendations. American Journal of Health-System Pharmacy 2022;79:63–71.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Azzolini E,
    2. Pozzi C,
    3. Germagnoli L,
    4. et al

    . mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients. Life Sci Alliance 2022;5.
16. 16.↵
    1. Gross CP,
    2. Essien UR,
    3. Pasha S,
    4. Gross JR,
    5. Wang S. y,
    6. Nunez-Smith M

    . Racial and ethnic disparities in population-level COVID-19 mortality. J GEN INTERN MED 2020;35:3097–9.

    OpenUrlPubMed
17. 17.↵
    1. Padamsee TJ,
    2. Bond RM,
    3. Dixon GN,
    4. et al

    . Changes in COVID-19 vaccine hesitancy among Black and White individuals in the US. JAMA Netw Open 2022;5:e2144470.

    OpenUrl
18. 18.↵
    1. Ndugga N,
    2. Hill L,
    3. Artiga S,
    4. Haldar S

    . Latest data on COVID-19 vaccinations by race/ethnicity. KFF. Published July 14, 2022. Accessed November 7, 2022. Available at: https://www.kff.org/coronavirus-covid-19/issue-brief/latest-data-on-covid-19-vaccinations-by-race-ethnicity/.
19. 19.↵
    1. Bazargan M,
    2. Cobb S,
    3. Assari S

    . Discrimination and medical mistrust in a racially and ethnically diverse sample of California adults. Ann Fam Med 2021;19:4–15.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Willis DE,
    2. Andersen JA,
    3. Bryant-Moore K,
    4. et al

    . COVID-19 vaccine hesitancy: race/ethnicity, trust, and fear. Clin Transl Sci 2021;14:2200–7.

    OpenUrlPubMed
21. 21.↵
    1. Willis DE,
    2. Andersen JA,
    3. Montgomery BEE,
    4. et al

    . COVID-19 vaccine hesitancy and experiences of discrimination among Black adults. J Racial and Ethnic Health Disparities. 2022;1–10. Published online April 7.
22. 22.↵
    1. Dada D,
    2. Djiometio JN,
    3. McFadden SM,
    4. et al

    . Strategies that promote equity in COVID-19 vaccine uptake for Black communities: a review. J Urban Health 2022;99:15–27.

    OpenUrlPubMed